137 articles|Clear filters
Christoph Röllig | EHA 2018 | 90 mg vs. 60 mg daunorubicin in 7+3 standard induction for ND AML
Cynthia Umukoro , Jun 19, 2018
General AML, TP53, FLT3, & 1 more
Lars Bullinger | EHA 2018 | What are the clinical implications of mutations in AML?
Cynthia Umukoro , Jun 18, 2018
General AML, IDH1/2
Julie Bergeron | EHA 2018 | What are the latest emerging novel approaches for treatment in AML?
Julie Bergeron , Jun 17, 2018
Musa Yilmaz | ASCO 2018 | Can relapse occur in AML patients after a long period of remission?
Cynthia Umukoro , Jun 11, 2018
Alice Mims | ASCO 2018 | What are the current challenges facing AML treatment?
Cynthia Umukoro , Jun 8, 2018